The APS workshop will take place during the morning of Wednesday 7th December at the EICC, before the main DDL2022 conference.

A number of the scientific and regulatory hurdles that exist for developing and registering new nasally-delivered therapies provide common challenges across the pharmaceutical industry. This meeting represents an opportunity to bring together members of the scientific community across industry and academia to discuss specific biopharmaceutics challenges around the development of nasally administered therapies. Aims of the symposium include exploring the need for a network for regular meetings and collaboration, and the development of a consensus of the state-of-the–art in nasal biopharmaceutics.

To find out more and to register please follow this link: https://ddl-conference.com/aps-workshop-at-ddl2022/